John de Groot
Impact in
Papers in
- Co-authors
- Yuji Piao (17 shared papers)Gregory N. Fuller (19 shared papers)Harald Sontheimer (1 shared paper)Amy B. Heimberger (21 shared papers)Monica Loghin (13 shared papers)Sudhakar Tummala (5 shared papers)Mark R. Gilbert (23 shared papers)William G. Wierda (1 shared paper)
- Journals
- Neuro-Oncology (62 papers)Journal of Neuro-Oncology (17 papers)Journal of Clinical Oncology (13 papers)Oncotarget (7 papers)Cancer Research (7 papers)
- Partner nations
- United StatesNetherlandsCanada
In The Last Decade
John de Groot
210 papers receiving 9.8k citations
John de Groot's Hit Papers
Peers
Comparison fields: 5 of 154
- Genetics 3.3k
- Oncology 3.0k
- Cancer Research 1.6k
- Immunology 1.6k
- Neurology 410
Countries citing papers authored by John de Groot
This map shows the geographic impact of John de Groot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John de Groot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John de Groot more than expected).
Fields of papers citing papers by John de Groot
This network shows the impact of papers produced by John de Groot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John de Groot. The network helps show where John de Groot may publish in the future.
Co-authors
The 25 scholars most cited alongside John de Groot, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 220 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Chimeric antigen receptor T-cell therapy — assessment and management of toxicities Hit paper breakdown → | 2017 | 1666 |
| 2 | Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study Hit paper breakdown → | 2015 | 441 |
| 3 | 2010 | 413 | |
| 4 | 2017 | 311 | |
| 5 | 2015 | 269 | |
| 6 | 2019 | 258 | |
| 7 | 2010 | 230 | |
| 8 | 2017 | 221 | |
| 9 | 2009 | 202 | |
| 10 | 2012 | 196 | |
| 11 | 2007 | 186 | |
| 12 | 2017 | 174 | |
| 13 | 2011 | 170 | |
| 14 | 2015 | 159 | |
| 15 | 1983 | 159 | |
| 16 | 2019 | 147 | |
| 17 | 2013 | 132 | |
| 18 | 2014 | 121 | |
| 19 | 2019 | 116 | |
| 20 | 2016 | 113 |
About John de Groot
John de Groot is a scholar working on Genetics, Oncology, Cancer Research, Molecular Biology and Pulmonary and Respiratory Medicine, having authored 220 papers that have together received 10.0k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (135 papers), Brain Metastases and Treatment (25 papers), Cancer, Hypoxia, and Metabolism (22 papers), Cancer Genomics and Diagnostics (21 papers), Radiomics and Machine Learning in Medical Imaging (14 papers), Angiogenesis and VEGF in Cancer (10 papers), Cancer Immunotherapy and Biomarkers (10 papers) and CAR-T cell therapy research (10 papers). The work is most often cited by research in Genetics (3.3k citations), Oncology (3.0k citations), Cancer Research (1.6k citations), Immunology (1.6k citations) and Neurology (410 citations). John de Groot has collaborated with scholars based in United States, Netherlands and Canada. Frequent co-authors include Yuji Piao, Gregory N. Fuller, Harald Sontheimer, Amy B. Heimberger, Monica Loghin, Sudhakar Tummala, Mark R. Gilbert, William G. Wierda, Suzanne E. Davis and Krishna V. Komanduri. Their work appears in journals such as Neuro-Oncology, Journal of Neuro-Oncology, Journal of Clinical Oncology, Oncotarget and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.